Childhood myeloproliferative neoplasm registry
Official title: The Myeloproliferative Neoplasms (MPN) Childhood Registry and Biobank
Run by University of Erlangen-Nürnberg Medical School · NCT07410247 · Data updated 2026-11-12
This registry will collect medical and genetic information from children and teens with MPNs to see if patterns emerge that can help doctors choose better care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 0 Years to 17 Years |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | University of Erlangen-Nürnberg Medical School Academic / other |
| Drugs / interventions | mepolizumab, benralizumab, ruxolitinib, imatinib, Tofacitinib, chemotherapy |
| Locations | 1 site (Erlangen, Bavaria) |
| Status | Recruiting |
| Started | January 1, 2023 |
| Main results expected | December 31, 2032 |
| Study ends | December 31, 2037 |
| Registry record updated | May 1, 2026 |
| Trial ID | NCT07410247 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children and adolescents under 18 years who are newly diagnosed with PV, ET, PMF, or pediatric HES, treated at a participating center, and whose guardians provide written consent are eligible.
✕Probably not a fit
Patients with secondary causes of polycythemia, thrombocytosis, myelofibrosis, or HES, as well as adults, are excluded and unlikely to benefit from this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational registry enrolls children and adolescents (under 18) newly diagnosed with BCR::ABL1-negative MPNs — polycythemia vera, essential thrombocythemia, primary myelofibrosis — or pediatric hypereosinophilic syndrome and collects clinical, laboratory, genetic, and treatment data. Patients are treated at participating centers and data are collected prospectively from diagnosis with planned long-term follow-up to document complications, transformation, and outcomes. The registry aims to describe disease features, treatment approaches, and long-term outcomes to support pediatric-specific diagnostic and therapeutic guidance. Participation involves no experimental interventions and relies on standard clinical care and data sharing.
Why it matters
Potential benefit: If successful, the registry could improve understanding of pediatric MPNs and lead to better diagnosis, risk stratification, and treatment guidance for children.
How similar studies have gone: Adult MPN registries have yielded useful clinical and genetic insights, but pediatric-focused registries are much rarer and data on children remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Newly diagnosed PV, ET, PMF or pHES * Age \< 18 years (up to 17 years and 365 days) at the day of diagnosis * Patient treated in a participating center * Written informed consent to registry participation Exclusion Criteria: o Secondary polycythemia, thrombocytosis, myelofibrosis or HES with underlying reasons other than PV, ET, PMF or pHES
Where it's running
-
Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany
Erlangen, Bavaria, Germany Recruiting
Study contacts
- Principal investigator: Axel Karow, MD — Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany
- Study coordinator: Axel Karow, PD Dr. med.
- Email: axel.karow@uk-erlangen.de
- Phone: +4991318541376
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Erlangen Stroke Registry: A long-running look at stroke in a German community
This registry is testing how stroke cases are collected and followed over time in Erlangen to understand how many people are affected and how care evolves.
-
Digital Dementia Registry Bavaria: a multicenter, long-term registry of people with mild cognitive impairment and dementia and their family caregivers
This registry will collect long-term health and care data from people with mild cognitive impairment or dementia in Bavaria and their caregivers to understand how dementia progresses and how care is provided.
-
Imaging of heart and lung changes after childhood cancer treatment in ALL or lymphoma
This study tests whether MRI, MSOT, and echocardiography can detect lasting heart and lung changes in adults who were treated for ALL or lymphoma in childhood, compared with healthy controls.
-
SP16 to help prevent kidney injury during cardiac surgery in people with CKD
Researchers are testing SP16 to see if it can prevent acute kidney injury in adults with chronic kidney disease who are having heart surgery that uses a heart-lung machine.
-
Omega-3 supplements plus progressive resistance training for cancer-related muscle loss
This study tests whether fish oil and a structured resistance-training program can help improve muscle status in adults with various cancers who are receiving treatment.
-
Imaging tiny kidney blood vessels in adults with proteinuria or active urinary sediment using ultrasound localization microscopy
This project will use a special ultrasound method called Ultrasound Localization Microscopy (ULM) to see if it can non-invasively show and measure tiny blood vessels in adult kidneys of people with proteinuria or active urinary sediment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.